China has closed tens of thousands of manufacturing plants across the country in an effort to reduce serious air pollution, and generics maker Stada says China’s crackdown has created supply problems.
Ronald Seeliger, eastern European regional chief for German generics maker Stada, told Bloomberg that China’s actions have interrupted deliveries, making it more important for the drugmaker to take some production in-house, although it still must rely on Chinese API makers.
“That’s having a big, big impact on us,” Seeliger told the news service last week. “Stada is seeking to insource many more products, to produce them in-house for better availability, better costs, reliable quality and for better logistics.”
One project that will help that effort, Seeliger said, is the a new packaging plant that Stada’s Hemofarm unit in Serbia will officially open this year. The €22 million ($27 million) plant in Vršac, Serbia, will allow the drugmaker to separate production from packaging. Stada has said the 600 square meter facility can fill 75 million ampoules annually.
The supply issues come even as the drugmaker is looking to expand in Eastern Europe following its $6.7 billion takeover by private equity partners Bain Capital and Cinven, who have replaced the board and named drug industry veteran Claudio Albrecht as its new CEO.
According to news reports, Chinese officials last fall closed up to 40% of the country’s manufacturing sites at some point for inspections of environmental standards. NPR earlier reported more than 80,000 factories were issued fines or criminal offenses as a result of their emissions, as safety officials did rolling inspections through dozens of Chinese provinces, causing supply interruptions for companies worldwide.
By Eric Palmer
Source: Fierce Pharma
In 2017, Sanofi partnered with the Lebanon, New Hampshire-based ImmuNext to develop an antibody for autoimmune diseases like lupus and multiple sclerosis, which included giving Sanofi a worldwide license to develop frexalimab. The agreement involved milestone payments upto $500 million.
Global manufacturer for the pharmaceutical, biotech and nutraceutical markets, Lonza has announced that it has acquired Synaffix, a biotech company focused on the commercialisation of its clinical stage technology platform for the development of antibody-drug conjugates (ADCs).
In its hunt for the new head of its pharmaceutical systems business—which makes syringes, self-injection systems and other drug delivery devices for 70% of the top 100 drugmakers in the world, according to the company—BD landed on a candidate with plenty of experience among that customer group.